Search for Stocks /

Thyrocare Technologies Q2 FY26 Concall Decoded: Bonus, Buffs & a Biochemistry Binge


1. Opening Hook

Thyrocare decided Diwali came early — not for patients, but shareholders. 🎆 A 2:1 bonus issue, a ₹7 interim dividend, and some serious self-praise about “affordable diagnostics for all.” Rahul Guha even dropped a Mandela quote before slipping in Six Sigma dreams and Tanzanian ambitions. Somewhere between HbA1c data and GLP-1 drugs, the call turned into a TED Talk on healthcare philosophy. Read on — it gets spicy when margins start flexing and radiology stops being the ugly stepchild.


2. At a Glance

  • Revenue up 22% – CFO swore it’s not COVID base math, just pure blood-test brilliance.
  • EBITDA margin 34.8% – Every pip squeezed like a lemon in a pathology beaker.
  • PAT up 82% YoY – Thyroid tests printing profits faster than printers print reports.
  • Gross margin 72% – Because needles don’t cost as much as servers.
  • Cash ₹190 Cr+ – Company so liquid it could test itself for hydration.
  • Bonus 2:1 + ₹7 Dividend – Diwali gift before anyone asked “What about us?”

3. Management’s Key Commentary

“Bonus shares 2:1 to commemorate 25 years of Thyrocare.”
(Because nothing says ‘Silver Jubilee’ like free paper wealth.)

“Our non-COVID growth over 4 years is 19% CAGR.”
(When COVID left the room, we finally found real growth.)

“We’ve achieved 100% NABL accreditation across all labs.”
(Translation: we can now officially brag in every investor meet.)

“Complaint rate down from 11.8% to 3.8%, aiming for Six Sigma.”
(Somewhere a consultant just

Read Full 16 Point breakdown. Continue reading →
Members get full access to every article.
Become a member
Already a member? Log in
Read Full 16 Point breakdown. Continue reading →